How and when are you using sipuleucel-T in metastatic prostate cancer given the increase in available treatment options?

At the present time, they do not. The options of treatment in the mHSPC setting include ADT, NHT, and docetaxel only. There are some ongoing clinical trials evaluating the combination of immune therapy with PD-1/PD-L1 checkpoint inhibitors and docetaxel or NHTs currently. Some phase II clinical tria...

I agree. Some of the factors I also use to optimally select patients most likely to have a substantial survival benefit with sip-T are PSA levels (lower levels associated with greater benefit potentially from IMPACT, and Sartor et al., PMID 32111923 and Higano et al., PMID 31483485 from PROCEED). Th...